Precigen Inc
PGEN1.754USD
+0.084+5.03%
Market hours （ET）Quotes delayed by 15 min
517.67MMarket Cap
LossP/E TTM
More Details of Precigen Inc Company
Precigen, Inc. is a dedicated discovery and clinical-stage biopharmaceutical company advancing gene and cell therapies. The Company’s proprietary technology platforms develops product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company operates through two segments: Biopharmaceuticals and Exemplar. Biopharmaceuticals segment is primarily comprised of the Company's legal entities of Precigen and ActoBio, as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. Exemplar segment is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar (Exemplar), its wholly owned subsidiary focused on developing research models and services for healthcare research applications.
Company Info
Ticker SymbolPGEN
Company namePrecigen Inc
IPO dateAug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
Number of employees143
Security typeOrdinary Share
Fiscal year-endAug 08
Address20374 Seneca Meadows Parkway
CityGERMANTOWN
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code20876
Phone13015569900
Websitehttps://precigen.com/
Ticker SymbolPGEN
IPO dateAug 08, 2013
CEODr. Helen Sabzevari, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
176.84K
+253.14%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
59.03K
+279.40%
Mr. Cesar L. Alvarez
Mr. Cesar L. Alvarez
Independent Director
Independent Director
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.32M
+20.22%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.15M
+12.00%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.14M
+11.34%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
595.77K
+26.11%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
579.24K
+27.13%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
520.43K
+32.30%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
No Data
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Service
1.11M
83.15%
Product
203.00K
15.14%
Other
23.00K
1.72%
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Third Security, LLC
39.41%
Merck Serono SA
6.99%
Patient Capital Management, LLC
5.89%
Adage Capital Management, L.P.
3.82%
BlackRock Institutional Trust Company, N.A.
3.24%
Other
40.65%
Shareholders
Shareholders
Proportion
Third Security, LLC
39.41%
Merck Serono SA
6.99%
Patient Capital Management, LLC
5.89%
Adage Capital Management, L.P.
3.82%
BlackRock Institutional Trust Company, N.A.
3.24%
Other
40.65%
Shareholder Types
Shareholders
Proportion
Venture Capital
39.41%
Investment Advisor
15.26%
Corporation
6.99%
Hedge Fund
6.47%
Investment Advisor/Hedge Fund
5.43%
Individual Investor
3.56%
Research Firm
0.41%
Bank and Trust
0.06%
Insurance Company
0.04%
Other
22.36%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
296
229.13M
77.63%
-805.74K
2025Q1
334
228.75M
77.50%
-12.95M
2024Q4
336
223.34M
76.44%
-15.36M
2024Q3
342
222.44M
77.88%
+21.14M
2024Q2
350
183.56M
71.33%
-22.34M
2024Q1
356
187.95M
73.95%
-17.15M
2023Q4
369
187.18M
73.43%
-12.81M
2023Q3
377
185.65M
75.06%
-11.67M
2023Q2
383
181.15M
73.32%
-8.55M
2023Q1
397
185.25M
75.25%
+14.81M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Third Security, LLC
116.34M
39.41%
-507.18K
-0.43%
Mar 31, 2025
Merck Serono SA
20.65M
6.99%
--
--
Mar 31, 2025
Patient Capital Management, LLC
17.37M
5.89%
-508.94K
-2.85%
Mar 31, 2025
Adage Capital Management, L.P.
11.28M
3.82%
+410.60K
+3.78%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
9.56M
3.24%
+209.48K
+2.24%
Mar 31, 2025
The Vanguard Group, Inc.
8.80M
2.98%
+465.47K
+5.59%
Mar 31, 2025
Iridian Asset Management LLC
4.59M
1.55%
-656.11K
-12.52%
Mar 31, 2025
Geode Capital Management, L.L.C.
3.48M
1.18%
+179.75K
+5.45%
Mar 31, 2025
Sabzevari (Helen)
3.32M
1.12%
+557.91K
+20.22%
May 16, 2025
Parkman Healthcare Partners LLC
3.19M
1.08%
+3.19M
--
Mar 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Inspire Small/Mid Cap ESG ETF
0.19%
iShares Micro-Cap ETF
0.05%
Invesco Nasdaq Biotechnology ETF
0.05%
ProShares Ultra Nasdaq Biotechnology
0.05%
Fidelity Enhanced Small Cap ETF
0.02%
iShares Biotechnology ETF
0.02%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
View more
Inspire Small/Mid Cap ESG ETF
Proportion0.19%
iShares Micro-Cap ETF
Proportion0.05%
Invesco Nasdaq Biotechnology ETF
Proportion0.05%
ProShares Ultra Nasdaq Biotechnology
Proportion0.05%
Fidelity Enhanced Small Cap ETF
Proportion0.02%
iShares Biotechnology ETF
Proportion0.02%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 Growth ETF
Proportion0.01%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
